Slingshot members are tracking this event:

Topline results released for Novartis' (NVS) Phase III study of ACZ885 (canakinumab) in reducing cardiovascular risk in people who survived a heart attack

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 22, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Acz885, Canakinumab, Heart Attack, Cardiovascular Risk